Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
17 pending office actions • 6 art units • 15 examiners • 0 of 17 (0%) have an AI response strategy ready • 10 patents granted in the last 365 days
Actinium Pharmaceuticals Inc. maintains a prosecution profile with 18 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 15 distinct examiners, indicating engagement with various patent office staff. The portfolio's activity spans 7 distinct art units, reflecting multiple technical applications within the biotechnology sector.
CABRAL, ROBERT S is the busiest examiner for this portfolio, currently managing 2 pending office actions. The remaining matters are spread across the other distinct examiners. This distribution shows that while CABRAL, ROBERT S has a higher workload than others, the majority of the pending office actions are handled by individual examiners. The involvement of 7 distinct art units suggests that the company's intellectual property is being reviewed by multiple specialized departments.
Practitioners should note that the volume of 18 pending office actions across 15 distinct examiners requires a coordinated strategy to ensure consistency. The distinct art units involved indicate that the portfolio faces various examination styles and technical standards. Managing these active matters effectively is critical for the company's patent strategy.
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 4 (24%) |
| Double-patenting only | 1 (6%) |
| Double-patenting + other | 3 (18%) |
| Multi-statute (no §101) | 9 (53%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SAMALA, JAGADISHWAR RAO | 2 | 68.0% | +55.6% |
| VU, JAKE MINH | 2 | 41.1% | +27.2% |
| WARD, PAUL V | 1 | 83.2% | -12.2% |
| CRAIG, KAILA ANGELIQUE | 1 | 33.8% | +25.2% |
| DICKINSON, PAUL W | 1 | 63.1% | +9.5% |
| SKOKO III, JOHN JOSEPH | 1 | 53.1% | +58.2% |
| BAEK, JONGHWAN NMN | 1 | 60.0% | +0.0% |
| SCHLIENTZ, LEAH H | 1 | 41.9% | +38.5% |
| DONOHUE, SEAN R | 1 | 41.4% | +21.0% |
| ROGERS, JAMES WILLIAM | 1 | 46.2% | +22.3% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18901169 | METHOD FOR TREATING CANCER USING A BCL-2 INHIBITOR IN CONJUNCTION WITH AN ALPHA-EMITTING RADIOIMMUNOTHERAPEUTIC | WARD, PAUL V | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16755590 | ANTI-CD45-BASED LYMPHODEPLETION METHODS AND USES THEREOF IN CONJUNCTION WITH ACT-BASED CANCER THERAPIES | JOHANSEN, PETER N. | 30d overdue |
| 16754400 | METHODS FOR CANCER TREATMENT USING A RADIOLABELED ANTI-CD45 IMMUNOGLOBULIN AND ADOPTIVE CELL THERAPIES | BUTTICE, AUDREY L | 33d |
| 18696453 | RADIOIMMUNOCONJUGATES TARGETING GRP78 FOR USE IN THE TREATMENT OF CANCER | DICKINSON, PAUL W | — |
| 18684103 | RADIOIMMUNOCONJUGATES TARGETING CALRETICULIN FOR USE IN THE TREATMENT OF CANCER | SAMALA, JAGADISHWAR RAO | — |
| 18036723 | METHODS FOR TREATING CANCER USING COMBINATIONS OF EPIGENETIC THERAPIES AND RADIOCONJUGATE TARGETING AGENTS | SCHLIENTZ, LEAH H | — |
| 18685667 | RADIOIMMUNOCONJUGATES TARGETING PHOSPHATIDYLSERINE FOR USE IN THE TREATMENT OF CANCER | VU, JAKE MINH | — |
| 17726296 | COMBINATION RADIOIMMUNOTHERAPY AND CD47 BLOCKADE IN THE TREATMENT OF CANCER | ROGERS, JAMES WILLIAM | — |
| 17606226 | COMPOSITIONS AND METHODS OF IMMUNODEPLETION FOR THE TREATMENT OF MALIGNANT AND NON-MALIGNANT HEMATOLOGICAL DISEASES | WESTERBERG, NISSA M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16627872 | TREATMENTS FOR A HEMATOLOGICAL MALIGNANCY | SAMALA, JAGADISHWAR RAO | 58d overdue |
| 18044356 | METHOD FOR TREATING ACUTE MYELOID LEUKEMIA USING VENETOCLAX IN CONJUNCTION WITH LINTUZUMAB-AC225 | DONOHUE, SEAN R | 11d overdue |
| 18887845 | METHODS FOR TREATING CANCER USING COMBINATIONS OF PARP INHIBITORS AND ANTIBODY RADIOCONJUGATES | CRAIG, KAILA ANGELIQUE | — |
| 18684103 | RADIOIMMUNOCONJUGATES TARGETING CALRETICULIN FOR USE IN THE TREATMENT OF CANCER | SAMALA, JAGADISHWAR RAO | — |
| 18557988 | RADIOIMMUNOCONJUGATES DIRECTED TO NKG2D LIGANDS FOR THE TREATMENT OF CANCER | SKOKO III, JOHN JOSEPH | — |
| 18036723 | METHODS FOR TREATING CANCER USING COMBINATIONS OF EPIGENETIC THERAPIES AND RADIOCONJUGATE TARGETING AGENTS | SCHLIENTZ, LEAH H | — |
| 18685667 | RADIOIMMUNOCONJUGATES TARGETING PHOSPHATIDYLSERINE FOR USE IN THE TREATMENT OF CANCER | VU, JAKE MINH | — |
| 17726296 | COMBINATION RADIOIMMUNOTHERAPY AND CD47 BLOCKADE IN THE TREATMENT OF CANCER | ROGERS, JAMES WILLIAM | — |
| Art Unit | Apps |
|---|---|
| 1618 | 8 |
| 1612 | 1 |
| 1614 | 1 |
| 1646 | 1 |
| 1644 | 1 |
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18901169 | METHOD FOR TREATING CANCER USING A BCL-2 INHIBITOR IN CONJUNCTION WITH AN ALPHA-EMITTING RADIOIMMUNOTHERAPEUTIC | WARD, PAUL V | — | DP | Non-Final OA | — | Pending | Sep 30, 2024 |
| 18887845 | METHODS FOR TREATING CANCER USING COMBINATIONS OF PARP INHIBITORS AND ANTIBODY RADIOCONJUGATES | CRAIG, KAILA ANGELIQUE | — | §103 | Non-Final OA | — | Pending | Sep 17, 2024 |
| 18696453 | RADIOIMMUNOCONJUGATES TARGETING GRP78 FOR USE IN THE TREATMENT OF CANCER | DICKINSON, PAUL W | — | §102§112 | Non-Final OA | — | Pending | Mar 28, 2024 |
| 18684103 | RADIOIMMUNOCONJUGATES TARGETING CALRETICULIN FOR USE IN THE TREATMENT OF CANCER | SAMALA, JAGADISHWAR RAO | — | §102§103 | Non-Final OA | — | Pending | Feb 15, 2024 |
| 18557988 | RADIOIMMUNOCONJUGATES DIRECTED TO NKG2D LIGANDS FOR THE TREATMENT OF CANCER | SKOKO III, JOHN JOSEPH | 1612 | §102§103§112DP | Non-Final OA | — | Pending | Oct 30, 2023 |
| 18553757 | RADIOIMMUNOTHERAPY DIRECTED TO CCR8 FOR DEPLETION OF TUMOR INFILTRATING REGULATORY T CELLS | BAEK, JONGHWAN NMN | 1618 | §103DP | Non-Final OA | — | Pending | Oct 03, 2023 |
| 18036723 | METHODS FOR TREATING CANCER USING COMBINATIONS OF EPIGENETIC THERAPIES AND RADIOCONJUGATE TARGETING AGENTS | SCHLIENTZ, LEAH H | 1618 | §102§103 | Non-Final OA | — | Pending | May 12, 2023 |
| 18044356 | METHOD FOR TREATING ACUTE MYELOID LEUKEMIA USING VENETOCLAX IN CONJUNCTION WITH LINTUZUMAB-AC225 | DONOHUE, SEAN R | 1618 | §103 | Final Rejection | 11d overdue | Pending | Mar 07, 2023 |
| 18685667 | RADIOIMMUNOCONJUGATES TARGETING PHOSPHATIDYLSERINE FOR USE IN THE TREATMENT OF CANCER | VU, JAKE MINH | 1618 | §103§112 | Final Rejection | — | Pending | Mar 02, 2023 |
| 17726296 | COMBINATION RADIOIMMUNOTHERAPY AND CD47 BLOCKADE IN THE TREATMENT OF CANCER | ROGERS, JAMES WILLIAM | 1618 | §103§112 | Non-Final OA | — | Pending | Apr 21, 2022 |
| 17725544 | COMBINATION RADIOIMMUNOTHERAPY AND CD47 BLOCKADE IN THE TREATMENT OF CANCER | CABRAL, ROBERT S | 1614 | §103§112DP | Non-Final OA | — | Pending | Apr 20, 2022 |
| 17702648 | COMBINATION RADIOIMMUNOTHERAPY AND CD47 BLOCKADE IN THE TREATMENT OF CANCER | CUNNINGCHEN, KATHLEEN MARY | 1646 | §103 | Final Rejection | 35d overdue | Pending | Mar 23, 2022 |
| 17606226 | COMPOSITIONS AND METHODS OF IMMUNODEPLETION FOR THE TREATMENT OF MALIGNANT AND NON-MALIGNANT HEMATOLOGICAL DISEASES | WESTERBERG, NISSA M | 1618 | §103§112 | Non-Final OA | — | Pending | Oct 25, 2021 |
| 17293663 | COMBINATION OF RADIOIMMUNOTHERAPY AND IMMUNE CHECKPOINT THERAPY IN THE TREATMENT OF CANCER | VU, JAKE MINH | 1618 | §102§103§112Other | Non-Final OA | — | Pending | May 13, 2021 |
| 16755590 | ANTI-CD45-BASED LYMPHODEPLETION METHODS AND USES THEREOF IN CONJUNCTION WITH ACT-BASED CANCER THERAPIES | JOHANSEN, PETER N. | 1644 | §103§112 | Non-Final OA | 30d overdue | Pending | Apr 12, 2020 |
| 16754400 | METHODS FOR CANCER TREATMENT USING A RADIOLABELED ANTI-CD45 IMMUNOGLOBULIN AND ADOPTIVE CELL THERAPIES | BUTTICE, AUDREY L | 1647 | §103§112 | Final Rejection | 33d | Pending | Apr 08, 2020 |
| 16627872 | TREATMENTS FOR A HEMATOLOGICAL MALIGNANCY | SAMALA, JAGADISHWAR RAO | 1618 | §103 | Final Rejection | 58d overdue | Pending | Dec 31, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial